Filana Therapeutics, Inc. FLNA
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -68.06% | -27.31% | |||
| Gross Profit | 68.06% | 27.31% | |||
| SG&A Expenses | 21.61% | -8.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.03% | -15.89% | |||
| Operating Income | -20.03% | 15.89% | |||
| Income Before Tax | -24.68% | 16.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.68% | 16.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.68% | 16.73% | |||
| EBIT | -20.03% | 15.89% | |||
| EBITDA | -20.93% | 16.26% | |||
| EPS Basic | -24.26% | 16.74% | |||
| Normalized Basic EPS | -24.26% | 16.75% | |||
| EPS Diluted | -22.94% | 15.85% | |||
| Normalized Diluted EPS | -24.26% | 16.75% | |||
| Average Basic Shares Outstanding | 0.32% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||